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Abstracts
Background: Allergic disease is a consequence of exposure to normally innocuous substances that elicit the
activation of mast cells. Mast-cell-mediated allergic response is involved in many diseases such as anaphylaxis,
urticaria, allergic rhinitis, asthma and allergic dermatitis. The development of food products for the prevention of
allergic disease is an important subject in human health. The chungkookjang (CKJ) has been reported to exhibit
antiallergic inflammatory activity. Therefore, the aim of the study is to examine the effects of the CKJ to reduce
histamine-induced wheal and flare skin responses.
Methods/Design: A randomized, double-blind, placebo-controlled study in 60 healthy subjects will be carried out.
Sixty volunteers (aged 20-80) who gave a written consent before entering the study will be randomized in two
groups of thirty subjects each. The skin prick test with histamine solution of 10 mg/ml will be performed on the
ventral forearm, 10 cm from the elbow. The subjects will be instructed to take 35 g per day of either the CKJ pills
or a placebo pills for a period of 3 months. Diameters of wheal and flare will be assessing 15 minutes after
performing the above-mentioned skin prick test. The primary outcome is change in wheal and flare responses.
Secondary outcomes will be include change in serum histamine, immunoglobulin E, cytokines (interferon-gamma,
interleukin-4, -10, and tumor necrosis factor-alpha), and eosinophil cationic protein.
Discussion: This study will show the potential anti-inflammatory properties of the CKJ in their skin activity when
histamine is the challenging agent as occurs in the clinical situation. And the present protocol will confirm the
efficacy and safety of the CKJ for allergy symptoms, suggesting more basic knowledge to conduct further
randomized controlled trials (RCT). If this study will be successfully performed, the CKJ will be an alternative dietary
supplemental remedy for allergy patients.
Trial Registration: NCT01402141
Background
Allergic reaction is a hypersensitive response caused by
immunoglobulin E (IgE)-dependent mast cell activation.
In response to IgE receptor cross-linking or other stimuli,
mast cells initiate exocytosis of the contents of secretory
granules. These include vasoactive amines, arachidonic
acid metabolites, chemokines, and cytokines [1,2]. These
pro-inflammatory mediators are responsible for activat-
ing mast cells in allergic inflammation and the hypersen-
sitive response [3-6]. Therefore, an agent or agents
capable of attenuating the production of these mediators
may be used as anti-inflammatory/anti-allergic agents.
Since the notion that a daily intake of certain food having
anti-allergic activity has the potential to reduce or elimi-
nate the need for drugs is generally accepted, the anti-
inflammatory/anti-allergic activities of the chungkook-
jang (CKJ) have been screened for this purpose [7].
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ean traditional food. It is prepared by fermenting
unsalted soybeans with Bacillus subtilis for several days.
It has a long history of popular use by the Korean peo-
ple and is sometimes used for topically for inflammatory
skin disorders. Several isoflavonoids such as genistein
and daidzein have been identified among the bioactive
compounds in the CKJ [8]. During the fermentation per-
iod, the content of the flavonoid aglycones increases
because of hydrolysis of the flavonoid glycosides [9].
The CKJ is also containing the poly-gamma-glutamic
acid (gamma-PGA). Gamma-PGA is an anionic polymer
that is composed of D- and L-glutamic acid units con-
nected by gamma-amide linkages between alpha-amino
and gamma-carboxylic acid groups [10]. Gamma-PGA is
mainly produced by Bacillus subtilis during fermenta-
tion processes of soybeans and not present in humans
[11]. Gamma-PGA is water soluble, biodegradable,
edible and non-toxic properties, raising interest in a
broad range of industries including food and cosmetics
[12]. Furthermore, recent reports have indicated anti-
allergic activity and immune modulatory activities of
gamma-PGA [7,13-16].
Histamine is one of the important mediators that elicit a
variety of symptoms such as wheal and flare response.
Since these histamine-related symptoms provoke the urge
to scratch, often impairing the quality of life, measures to
suppress and control these symptoms are required. In the
development of a new anti-histamine, the histamine-
induced wheal and flare skin test has been used most fre-
quently. The histamine-induced wheal and flare test is
based on the measurement of local swelling caused by
plasma extravasation (wheal) and reflex vasodilatation
(flare) after histamine challenge [17]. Therefore, the hista-
mine skin prick test may be useful for assessing aspects of
drug activity during the early clinical development of a
new anti-histamine.
The aim of this study is to evaluate the efficacy and
safety of the CKJ, a dietary supplement for the treatment
of allergic skin symptoms. This study will be first pilot
study about the improvement of skin hypersensitivity reac-
tion of the CKJ in healthy volunteers. The results of this
study will give us the clinical of biochemical parameters
such as IgE, histamine, and cytokines between the placebo
and CKJ groups. On the basis of the results, we will sug-
gest the optimal design, precise sample size, and primary
outcome for a further large scale RCT.
Methods/design
Study objectives
The objectives of this RCT are to study whether the CKJ
pills can alleviate the histamine-induced wheal and flare
skin responses in healthy subjects.
Primary objective
To evaluate the efficacy of the CKJ pills on histamine-
induced wheal and flare skin responses in healthy sub-
jects after 12 weeks of consumption.
Secondary objectives
To evaluate the following factors in healthy subjects
after 12 weeks of consumption on:
A) Change of IgE and histamine concentrations
B) Change of cytokines such as IFN-gamma, IL-4,
IL-10, and TNF-alpha
C) Change of eosinophil cationic protein
Ethics
The study protocol and the written informed consent
were approved by the Functional Foods Institutional
Review Board of Chonbuk National University Hospital
(CUH IRB 2010-02-007). Each participant will be noti-
fied regarding the study protocol. Written informed
consent will be obtained from each participant.
Study/trial design
This study is a randomized, double-blind, placebo-con-
trolled, two-armed parallel clinical trial, comparing the
CKJ pills to placebo pills. The design of the study will
integrate rigorous in accord with principles set out in
the Declaration of Helsinki and the Good Clinical
Practice guidelines. Our study plan is summarized in
Figure 1.
Inclusion criteria for participation in the trial
Inclusion criteria
Participants will be included if they meet the following
criteria:
A) Healthy volunteers aged 20 to 80 years
B) Positive response to histamine skin prick test(a
wheal size > 3 mm)
C) Ability to give informed consent
Exclusion criteria
Participants will be excluded if they:
A) have severe generalized skin conditions such as
eczema, psoriasis, and atopy(hay fever, asthma)
B) have severe allergic reactions in the past
C) have taken oral anti-histamines or topical corti-
costeroids in the preceding 3 months
D) have any acute or chronic illness
E) have cardiovascular disease, liver or kidney
disease
F) have allergies on soybean foods
Kwon et al. BMC Complementary and Alternative Medicine 2011, 11:125
http://www.biomedcentral.com/1472-6882/11/125
Page 2 of 6G) have taken any prescribed or investigation medi-
cation during the 8 weeks preceding enrolment.
H) have history of drug or alcohol abuse in prior 2
months
Recruitment
60 participants will be recruited through local advertis-
ing and doctor referrals from hospital outpatients and
general practice clinics. Interested participants can
telephone or email the trial coordinators at the trial
conducting sites for further information. Participant
information and consent forms will be sent to interested
individuals to read over prior to scheduling their first
visit.
Randomization
After enrollment, participants will be randomly assigned
to one of the two groups, either the CKJ pills group or
placebo pills group. The allocation ratio will be 1:1 in
Figure 1 Flow diagram for study. Summary of the study flow.
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remote from trial location. Random numbers will be
generated by a computerized random-number generator
through the block-randomization method of a software
program (Excel, Microsoft Office 2007) for sequence
generation. At the time of randomization participants
will draw an envelope. Each envelope contains a number
that is concealed to the treatment allocation. Randomi-
zation sequence and allocation will be concealed to all
study subjects, research staff, investigators and pharma-
cists until completion of the study. The allocation list
will be protected by password access files and held by a
non-investigator independent. In the event of an emer-
gency medical situation the individual’s randomization
code and group allocation can be identify.
Outcome measures
Primary outcome
The primary outcome is the difference on wheal and flare
skin responses induced by histamine challenge at baseline
and three months after randomization. The histamine-
induced wheal and flare skin test will be performed by his-
tamine challenge via epicutaneous prick. The resulting
wheal is a sign of the direct vascular effects of histamine,
namely increased vascular permeability and skin blood
flow, while the flare reflects vasodilatation due to
histamine-induced reflex neuropeptide release from local
nerve terminals. The wheal and flare response will be
assessed 15 min after the test and will be assessed as the
mean diameter or by planimetry.
Secondary outcomes
Secondary outcomes will be shown by the mean change of
IgE, histamine, eosinophil cationic protein, IFN-gamma,
IL-4, IL-10, and TNF-alpha. These biomarkers will be
checked at weeks 0 (baseline) and 12 (end of the trial).
The schedule of assessments is presented in Table 1.
Statistical analysis
Baseline data and Outcomes data
Statistical analysis will be performed using SAS version
9.0 for Windows (SAS Institute, Cary, NC, USA). Data
will be presented as mean±SD values. The Chi-square
test will be performed to determine differences at base-
line in frequencies of categorized variables between the
groups. A linear mixed-effects model will be applied to
repeated-measures data for each continuous outcome
variable. Fixed effects will be included treatment group,
treatment visit, and interaction between treatment group
and visit. When the analysis of variance indicated signifi-
cant differences among groups, post hoc test (Turkey’s
test) will be used to separate the differences between
groups before and after the 12-week intervention period.
Table 1 A brief study schedule at every visit
Screening Visit 1 Baseline Visit 2 Visit 3 Visit 4 Visit 5 Follow up (Visit 6)
D-21 ~D-1 Week 0 D0 Week 4 D28 Week 8 D56 Week 12 D84 Week 16 D112
Informed consent form ◯
Demographic information taking
1 ◯
Medical history taking ◯
Inclusion/exclusion criteria check ◯◯
Physician examination
2 ◯◯
Drinking/smoking taking status
3 ◯◯
Vital sign measurement ◯◯ ◯ ◯ ◯
Concomitant drugs check ◯◯ ◯ ◯ ◯
Electrocardiogram(ECG) ◯◯
Histamine skin prick test ◯◯
Laboratory test
4 ◯◯
Histamine & ECP ◯◯
Study product distribution ◯◯ ◯
Compliance checking ◯◯ ◯
Adverse event monitoring ◯◯ ◯ ◯
Diet, physical exercise counseling
5 ◯◯ ◯
◯ : Item need to be performed during the visit
1 Sex, date of birth, age, contact address and phone number
2 Include present illness, past history taking
3,5 Risk factors such as alcohol drinking, smoking, severe exercise and other dietary supplement intake will be managed
4 Blood test(WBC, RBC, hemoglobin, hematocrit, platelets count, AST, ALT, ALP, gamma-GTP, albumin, BUN, creatinine, glucose, total bilirubin, total protein, total-
cholesterol, triglyceride, LDL-C, HDL-C, IgE), urine test(specific gravity, pH, Protein, Ketone, Glucose, bilirubin, urobilinogen, nitrite, microscopic (RBC, WBC))
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Adverse events and monitoring safety
All unexpected adverse events related to CKJ pills intake
will be reported to the investigator by participants and
write on the individual case report form by the investiga-
tor. Safety will be assessed by the reporting of clinical
laboratory tests, vital sign measurements, and adverse
events. Clinical laboratory tests, including AST/ALT,
BUN/creatinine, red blood cell (RBC) count, white blood
cell (WBC) count, hemoglobin, hematocrit, number of pla-
telets, and number of differentiated cells will be deter-
mined at weeks 0 (baseline) and 12 (end of the trial). Vital
signs of each participant will be checked with monitoring
of adverse events (nausea/vomiting, fatigue, allergic reac-
tion, and any adverse events related to CKJ pills) after
each visit.
Compliance
The CKJ pills remaining after each visit will be quanti-
fied in order to enhance medication compliance. Partici-
pants whose compliance with the CKJ pills is ≤ 70% of
the total dose will be considered to have dropped-out.
Sample size
Sample size calculation is performed; primary outcome
measure will be the histamine-induced wheal size,
whereby 5.0 square millimeters is assumed a clinically
relevant difference between the two groups, with a stan-
dard deviation of 6.85, alpha set on 5% and power on 80%.
This resulted in a required number of 24 subjects in each
group. Assuming a dropout rate of 20%, a total of 60 sub-
jects will be enrolled in this trial.
Discussion
The use of histamine-induced wheal and flare skin
responses to demonstrate the antihistamine activity is a
widely accepted and well established method.
T h ea i mo ft h i ss t u d yi st oe v a l u a t et h ea n t i h i s t a m i n e
effect of the CKJ on the skin quantitatively. For this pur-
pose, the ability of the CKJ to suppress the histamine-
induced wheal and flare skin responses will be assessed
in 60 healthy volunteers.
In this study, we expect that the CKJ effectively suppress
the wheal and flare skin responses. Many studies have
assessed the relative potency of antihistamines by measur-
ing their ability to suppress the histamine-induced wheal
and flare skin responses. To the best of our knowledge,
there has been no report demonstrating the CKJ. There-
fore, if this study will be successfully performed, the CKJ
may offer beneficial effects in preventing the various
allergy symptoms. And these results will have important
implications for the design of sustainable cost-effective
health services for people with mild allergic diseases. In
addition, this study will be the groundwork for the larger
scale RCT. To draw confirmative conclusion about the
therapeutic efficacy and safety of the CKJ, a full-scale RCT
will be performed.
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